CHINA China to accelerate price cuts of anti-cancer drugs

CHINA

China to accelerate price cuts of anti-cancer drugs

CGTN

02:40, July 15, 2018

24313f00d669413daf0f32013cfe3960.jpg

(Photo: CGTN)

The National Medical Insurance Bureau will carry out negotiations on the entry of anti-cancer drugs for medical insurance in 2018 in a bid to accelerate price cuts.

The whopping prices and the shortage of anti-cancer drugs have caught much attention in China, and the state medical insurance authority have been taking measures to improve the medical insurance system by introducing policies and encouraging innovations.

Since May 1, China has implemented zero tariffs on imported anti-cancer drugs.

On June 20, China decided during the State Council executive meeting to speed up the examination and approval of imported new drugs, to accelerate the price cuts of anti-cancer drugs and ensure the supply of scarce drugs.

Anti-cancer drugs already covered by state insurance will have their prices cut through bidding and procurement process, and market competition. 

For anti-cancer drugs not covered by state insurance, which is an urgent matter to be addressed, will be covered and reasonably priced through negotiations by related departments with considerations of clinical demands and company profits.

Most frequently used anti-cancer drugs with therapeutic effects have already been included into medical insurance catalog, according to people in charge of the matter.

In 2017, 15 cancer treatment drugs with therapeutic effects were included, such as Herceptin, Rituximab and Bortezomib.

Multinational drug makers take the initiatives

Some insiders believe that some imported drugs face the pressures of expiration of patents and competitions from cheaper domestic drugs with the same effects. Therefore, some multinational drug makers resort to boost sales and secure the market by cutting prices.

Pfizer and Xian-Janssen have already applied to cut prices of some drugs. Imported drugs including capsules, tablets and injections produced in the United States, France, Germany, Australia, Spain, Italy and the Netherlands are also among the list to cut price, according to Beijing Pharmaceutical Purchasing Service Center.

Related Stories

Terms of Service & Privacy Policy

We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies

Agree and continue